AVROBIO Revenue and Competitors
Estimated Revenue & Valuation
- AVROBIO's estimated annual revenue is currently $21.2M per year.
- AVROBIO's estimated revenue per employee is $331,797
- AVROBIO's total funding is $85M.
Employee Data
- AVROBIO has 64 Employees.
- AVROBIO grew their employee count by -36% last year.
AVROBIO's People
Name | Title | Email/Phone |
---|---|---|
1 | VP Information Technology | Reveal Email/Phone |
2 | Senior Director, FP&A | Reveal Email/Phone |
3 | Director IT Operations | Reveal Email/Phone |
4 | Senior Director, External Manufacturing & Relations Management | Reveal Email/Phone |
5 | Sr. Clinical Trial Manager | Reveal Email/Phone |
6 | Senior Manager Manufacturing | Reveal Email/Phone |
7 | Office Manager | Reveal Email/Phone |
8 | Program Leader | Reveal Email/Phone |
AVROBIO Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 1 | -50% | N/A | N/A |
#3 | $5.1M | 33 | 22% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 2 | -60% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | N/A | 11 | 10% | N/A | N/A |
#10 | $5.4M | 29 | 0% | N/A | N/A |
What Is AVROBIO?
Clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
keywords:N/A$85M
Total Funding
64
Number of Employees
$21.2M
Revenue (est)
-36%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AVROBIO News
2022-04-20 - Analysts Anticipate AVROBIO, Inc. (NASDAQ:AVRO) Will Post ...
Analysts Anticipate AVROBIO, Inc. (NASDAQ:AVRO) Will Post Earnings of -$0.58 Per Share. Posted by admin on Apr 24th, 2022.
2022-04-17 - Is Avrobio Inc (AVRO) Stock at the Top of the Biotechnology Industry?
Avrobio Inc (AVRO) is around the middle of the Biotechnology industry according to InvestorsObserver. AVRO received an overall rating of 37,...
2022-04-06 - AVROBIO, Inc. (NASDAQ:AVRO) Receives $7.84 Average ...
AVROBIO, Inc. (NASDAQ:AVRO) Receives $7.84 Average Price Target from Analysts. Posted by admin on Apr 12th, 2022.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.1M | 64 | -11% | $55.9M |
#2 | $17.4M | 64 | 7% | $434.6M |
#3 | $28.7M | 64 | -2% | N/A |
#4 | $15.9M | 64 | -2% | N/A |
#5 | $7.5M | 64 | 21% | N/A |